Clik here to view.
Personalis推出基于肿瘤信息的液相活检分析法NeXT Personal™，检测MRD和复发的灵敏度可达百万分之一
加州门洛帕克 (美国商业资讯)–先进癌症基因组学的领导者Personalis, Inc. (Nasdaq: PSNL)今天宣布推出NeXT Personal，这是一种新一代基于肿瘤信息的液相活检分析方法，旨在检测和量化有既往癌症诊断史患者的分子残留疾病(MRD)和复发。NeXT...
View ArticleClik here to view.
BeiGene Announces Launch of Bioisland Innovation Center
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today...
View ArticleClik here to view.
Curia Unveils Comprehensive mRNA Solution
ALBANY, N.Y. Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process...
View ArticleClik here to view.
Babson Graduate Pooja Ika Launches eternalHealth, the First New Medicare...
BOSTON eternalHealth, the first new health plan to be approved in Massachusetts since 2013, has officially announced its launch of the company, delivering high-quality and affordable Medicare...
View ArticleClik here to view.
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P....
View ArticleClik here to view.
イクスーダ・セラピューティクス、レゴケム・バイオサイエンシズからのHer2抗体薬物複合体プログラムのライセンス契約により、臨床パイプラインを強化
英ニューカッスル （ビジネスワイヤ） — 治療指数を高めた新世代の抗体薬物複合体（ADC）の開発を手掛けるイクスーダ・セラピューティクス（イクスーダ）は本日、専有的な創薬技術を活用した次世代の新規治療薬の開発に傾注する韓国のバイオ製薬企業レゴケム・バイオサイエンシズ（LCB）とライセンス／商業化契約を結び、当社の差別化ADCパイプラインをさらに拡大すると発表しました。...
View ArticleClik here to view.
Iksuda Therapeutics与LegoChem Biosciences签署Her2抗体药物偶联物项目许可协议以深化临床产品线
英国纽卡斯尔 (美国商业资讯)–开发新一代高治疗指数抗体药物偶联物(ADC)的公司Iksuda Therapeutics (Iksuda)今天宣布，将通过与韩国生物制药公司LegoChem Biosciences (LCB)所签的许可和商业化协议，进一步扩大公司差异化的ADC产品线。LCB专注于运用其专有药物发现技术开发下一代新型治疗药物。 该协议向Iksuda提供LCB的Her2...
View ArticleClik here to view.
Parse Biosciences Announces Partnership With Research Instruments Group to...
SEATTLE Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to provide Parse’s Evercode Whole...
View ArticleClik here to view.
EdiGene Enters Strategic R＆D Collaboration with Haihe Laboratory of Cell...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
The Japan Prize Foundation: 2022 Japan Prize Laureates Announced
TOKYO The Japan Prize Foundation announced the winners of the 2022 Japan prize today. Prof. Katalin Karikó (Hungary/USA) and Prof. Drew Weissman (USA) are co-winners of the Japan Prize in the fields...
View ArticleClik here to view.
日本奖基金会公布2022年“日本奖”获得者名单
东京 (美国商业资讯)–日本奖基金会(The Japan Prize Foundation)今日公布了2022年“日本奖”的获奖名单。Katalin Karikó教授（匈牙利裔/美国）和Drew Weissman教授（美国）共同获得“材料与生产”领域的日本奖，Christopher Field教授（美国）获得“生物生产、生态/环境”领域的日本奖。...
View ArticleClik here to view.
ウォーターズが電荷検出質量分析技術を取得し、その細胞・遺伝子治療への応用を拡大
米マサチューセッツ州ミルフォード （ビジネスワイヤ） — ウォーターズコーポレーション (NYSE:WAT) は本日、電荷検出質量分析法 (CDMS) の技術とサービスの初期段階の開発企業であるメガダルトン・ソリューションズの技術資産と知的財産権を取得したと発表しました。本取引の財務的な詳細は公開していません。...
View ArticleClik here to view.
Clik here to view.
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of...
View ArticleClik here to view.
New Study Validates Novel Markers for Detecting Microsatellite Instability in...
MADISON, Wis. Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI)...
View ArticleClik here to view.
BeiGene to Present at the Guggenheim Healthcare Talks – 2022 Oncology Conference
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the...
View ArticleClik here to view.
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
沃特世收购电荷检测质谱技术，扩展其在细胞和基因治疗中的应用
马萨诸塞州米尔福德 (美国商业资讯)–沃特世公司(Waters Corporation, NYSE:WAT)今天宣布已经收购了电荷检测质谱(CDMS)技术和服务早期开发商Megadalton Solutions, Inc.的技术资产和知识产权。该交易的财务细节没有披露。 Megadalton Solutions由印第安纳大学的Martin Jarrold教授和David...
View ArticleClik here to view.
武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda, TOKYO:4502/NYSE:TAK)今天公布了强劲的2021财年第三季度业绩（截至2021年12月31日的期间），这一业绩得益于其14个全球品牌稳健的营收增长。基于强劲的第三季度业绩和业务势头，武田更新了整个财年营收、列报经营利润和核心经营利润、列报每股收益和核心每股收益以及自由现金流的预测。...
View ArticleClik here to view.
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell...
BEIJING & SHANGHAI & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious...
View Article